Cargando…

Benefits of nirmatrelvir–ritonavir remain unproven for some populations

Detalles Bibliográficos
Autores principales:	McDonald, Emily G., Lee, Todd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Impact Inc. 2022
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481259/ https://www.ncbi.nlm.nih.gov/pubmed/35918091 http://dx.doi.org/10.1503/cmaj.146689-l

Ejemplares similares

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19
por: Graziani, Lucia, et al.
Publicado: (2022)

Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 for patients with dementia
por: Liu, Ting-Hui, et al.
Publicado: (2023)

Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
por: Gao, Yuan, et al.
Publicado: (2023)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series
por: Vazquez, Sara R., et al.
Publicado: (2022)

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
por: Patel, Dimple, et al.
Publicado: (2023)

Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
por: Savinkina, Alexandra, et al.
Publicado: (2022)

Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis
por: Li, Huamin, et al.
Publicado: (2023)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients
por: Catalán, Ignacio Pérez, et al.
Publicado: (2022)

Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease
por: Hoertel, Nicolas, et al.
Publicado: (2022)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
por: Kim, Haein, et al.
Publicado: (2022)

Correction to: Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing—A Cost-effectiveness Analysis
Publicado: (2023)

Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
Publicado: (2022)

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
por: Cao, Zhujun, et al.
Publicado: (2022)

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
por: Blair, Hannah A.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_emo36feq61sohi0eripbtpnl8e